Prostate CancerThe association of metabolic syndrome and its components with serum prostate-specific antigen levelsGao, Xiaoshuaia,,*; Bao, Tingb,,*; Yang, Hanweib; Lei, Yalib; Jiang, Xianwenb; Huang, Yanb; Huang, Wenxiac; Tang, HuairongbAuthor Information aDepartment of Urology, Institute of Urology (Laboratory of Reconstructive Urology) Departments of bHealth Management Center cEquipment and Material, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China Received 5 August 2018 Accepted 19 January 2019 * Xiaoshuai Gao and Ting Bao contributed equally to the writing of this article. Correspondence to Huairong Tang, MD, Department of Health Management Center, West China Hospital, Sichuan University, Guo Xue Xiang 37, Chengdu 610041, Sichuan Province, People’s Republic of China, Tel: +86 177 135 83409; fax: +86 28 028 8542 3466; e-mail: email@example.com European Journal of Cancer Prevention: January 2020 - Volume 29 - Issue 1 - p 36–41 doi: 10.1097/CEJ.0000000000000508 Buy Metrics Abstract Metabolic syndrome (MetS) can increase the risk of prostate cancer. Prostate-specific antigen (PSA) is the marker for prostate cancer puncture screening. The aim of our study was to investigate the association between MetS and its components with PSA levels. Data were obtained from 482 943 healthy men who underwent routine health check-ups from January 2010 to December 2017. We used linear regression analysis to evaluate the effects of MetS and its components on PSA levels. To explore the cumulative effect of MetS components, analysis of variance trend analysis was carried out. The PSA levels in the group with MetS were significantly lower than those without MetS (P = 0.001). In the multivariate regression model, age (P < 0.001) and hypertension (P < 0.001) were correlated positively with PSA levels; nevertheless, obesity (P < 0.001), hypertriglyceridemia (P < 0.001), hyperglycemia (P < 0.001), and low high-density lipoprotein cholesterol level (P < 0.001) had a negative correlation. In addition, after adjustment for age, increasing sums of positive MetS components were associated with a linear decrease in PSA levels (P<0.001). In conclusion, MetS, obesity, hypertriglyceridemia, hyperglycemia, and low high-density lipoprotein cholesterol levels are associated with decreased PSA levels. For patients with PSA levels at the critical value of prostate puncture, the effect of these diseases in reducing PSA levels should be taken into account. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.